Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CTLT Catalent
53.650+1.380+2.64%
Close
01/27 16:00 ET
53.6500.0000.00%
Post Mkt Price 01/27 16:03 ET
High
54.120
Open
52.250
Turnover
92.98M
Low
51.930
Pre Close
52.270
Volume
1.75M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Is Catalent, Inc.'s (NYSE:CTLT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Barclays Lowers Catalent (NYSE:CTLT) Price Target to $58.00
Catalent (NYSE:CTLT – Get Rating) had its price target cut by Barclays from $62.00 to $58.00 in a research note published on Tuesday, The Fly reports. They currently have an overweight rating on the
Catalent, Inc. to Post FY2023 Earnings of $2.95 Per Share, Jefferies Financial Group Forecasts (NYSE:CTLT)
Catalent, Inc. (NYSE:CTLT – Get Rating) – Analysts at Jefferies Financial Group increased their FY2023 earnings per share (EPS) estimates for Catalent in a report issued on Tuesday, January 24th.
Catalent (NYSE:CTLT) Price Target Cut to $58.00
Catalent (NYSE:CTLT – Get Rating) had its target price lowered by Barclays from $62.00 to $58.00 in a report released on Tuesday, The Fly reports. The brokerage currently has an "overweight" rating
Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)
Catalent, Inc. (NYSE:CTLT – Get Rating) – Analysts at Jefferies Financial Group upped their Q2 2023 EPS estimates for shares of Catalent in a report released on Tuesday, January 24th. Jefferies Fi
Bank Julius Baer & Co. Ltd Zurich Reduces Stake in Catalent, Inc. (NYSE:CTLT)
Bank Julius Baer & Co. Ltd Zurich lowered its position in Catalent, Inc. (NYSE:CTLT – Get Rating) by 16.1% during the third quarter, according to the company in its most recent disclosure with the S
Catalent (NYSE:CTLT) Trading Down 4.1% on Analyst Downgrade
Catalent, Inc. (NYSE:CTLT – Get Rating)'s stock price was down 4.1% on Tuesday after Barclays lowered their price target on the stock from $62.00 to $58.00. Barclays currently has an overweight ratin
Catalent Launched New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of its new Case Management Service, which has been specifically desi
Barclays Adjusts Catalent's Price Target to $58 From $62, Maintains Overweight Rating
09:01 AM EST, 01/24/2023 (MT Newswires) -- Catalent (CTLT) has an average rating of Outperform and price targets ranging from $58 to $100, according to analysts polled by Capital IQ.
Catalent Is Maintained at Overweight by Barclays
Catalent Is Maintained at Overweight by Barclays
Company Overview
More
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
CEO： Mr. Alessandro Maselli
Market： NYSE
Listing Date： 07/31/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet